Business Context and Reporting Period
uniQure N.V., an emerging growth company incorporated in The Netherlands, filed this Form 8-K on December 10, 2018, reporting events occurring on December 6, 2018. The filing details a material definitive agreement regarding the refinancing and expansion of its credit facility.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. The primary financial data relates to debt financing:
- Total Facility Size: $50 million (refinanced $20 million existing facility plus $30 million new commitment).
- Discretionary Portion: $15 million of the new commitment is subject to Hercules Technology Growth Capital Inc.'s discretion.
- Drawdowns: $15 million drawn at signing; an additional $15 million available through June 30, 2020.
- Outstanding Debt at Signing: $35 million.
- Interest Rate: Adjustable, the greater of 8.85% or 8.85% plus the prime rate less 5.50%.
- Fees: 0.50% facility fee on outstanding debt; 4.95% back-end fee on outstanding debt.
- Maturity Date: Extended to June 1, 2023.
Material Changes Versus Prior Period
The company amended its Second Amended and Restated Loan and Security Agreement with Hercules Technology Growth Capital Inc. Key changes include:
- Capacity Increase: Total commitment increased from $20 million to $50 million.
- Term Extension: Maturity date extended to June 1, 2023.
- Interest-Only Period: Extended from November 2018 to January 1, 2021. This period may extend to January 1, 2022, if the company raises over $90 million in a corporate transaction or completes a Phase 3 pivotal study of AMT-061 for Hemophilia B with supportive clinical results.
- Repayment Structure: Principal and interest repayments will occur in equal monthly installments following the interest-only period.
Guidance, Outlook, and Risks
Management commentary is limited to the terms of the new financing. The filing highlights specific milestones that could extend the interest-only period, specifically the completion of a Phase 3 pivotal study for AMT-061 or a significant capital raise. The filing does not provide general business guidance or discuss other risks beyond the terms of the debt agreement.
Investor Verification Checklist
- Verify the exact terms of the "discretionary" $15 million commitment and the conditions required to access it.
- Confirm the current status of the AMT-061 Phase 3 pivotal study for Hemophilia B to assess the likelihood of extending the interest-only period to 2022.
- Review the full text of Exhibit 10.1 (Amendment No. 1) for covenants and default provisions not summarized in the 8-K.
- Monitor the company's cash burn rate relative to the $35 million outstanding debt and the remaining $15 million available drawdown.